Inotek Pharmaceuticals Corporation Reports Fiscal Year 2016 Financial Results and Operational Highlights

Inotek Pharmaceuticals Corporation Reports Fiscal Year 2016 Financial Results and Operational Highlights

LEXINGTON, Mass. March 16, 2017 Inotek Pharmaceuticals Corporation (NASDAQ:ITEK), a clinical-stage

biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today reported financial results and operational highlights for the fiscal year ended December 31, 2016.

In 2016, Inotek completed the Phase 3 MATrX-1 clinical trial of trabodenoson for the treatment of primary

open-angle glaucoma and/or ocular hypertension and also initiated a Phase 2 trial to identify a potential fixed-dose combination of trabodenoson and latanoprost for the same indications, said David P. Southwell, President and

Chief Executive Officer of Inotek. While MATrX-1 did not achieve its primary endpoint, superiority in reduction of mean intraocular pressure (IOP) compared to placebo, we believe this result was driven

by placebo outliers at a few trial sites.

We intend to discuss the full MATrX-1 data set with the US

Food and Drug Administration in the first half of 2017 to determine next steps for the clinical development of the monotherapy program, added Mr. Southwell. In addition, the Phase 2 fixed-dose combination study of

trabodenoson with latanoprost, addressing a considerably larger market opportunity than monotherapy, is fully enrolled and we expect to report top-line data in

mid-2017. Based on the results of this trial, we will determine next steps for the clinical development of this combination therapy.

Recent Trabodenoson Development Program Highlights:

Full Year 2016 Financing Highlights:

Fiscal Year 2016 Financial Results:

Inotek Pharmaceuticals Corporation

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and

commercialization of therapies for glaucoma and other eye diseases. The Company s lead product candidate, trabodenoson, is a first-in-class selective

adenosine mimetic currently in Phase 3 development. Trabodenoson was developed in Inotek s laboratories and is designed to restore the eye s natural pressure control mechanism. Additionally, the Company is evaluating the potential

for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases. For more information, please visit www.inotekpharma.com. The inclusion of our website address here and elsewhere in this press release

does not include or incorporate by reference the information on our website into this press release.

Forward-Looking Statements

Various statements in this release concerning Inotek s future expectations, plans and prospects, including without limitation, Inotek s expectations

regarding the use of trabodenoson and its fixed-dose combination (FDC) program with latanoprost as treatments for primary open-angle glaucoma or ocular hypertension, Inotek s expectations regarding reporting top-line data of its Phase 2 trial for its FDC, Inotek s expectations with respect to the timing and success of its clinical studies and pre-clinical studies for

trabodenoson, its FDC, orphan diseases, and the possibility of selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases, may constitute forward-looking statements for the purposes of the safe harbor

provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward looking statements, which

often include words such as believe, expect, anticipate, intend, plan, will give, estimate, seek, will, may suggest

or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Actual results may

differ materially from those indicated by

these forward-looking statements as a result of various important factors, including, without limitation, Inotek s ability to successfully demonstrate the efficacy and safety of

trabodenoson, its FDC program, its pre-clinical studies for orphan diseases, or selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases, the pre-clinical and clinical results for its product candidates, which may not support further development and marketing approval, the potential advantages of Inotek s product candidates, actions of regulatory

agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Inotek s ability to obtain, maintain and protect its intellectual

property, Inotek s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, the timing, cost or other aspects of a potential commercial launch of Inotek s product candidates

and potential future sales of our current product candidates or any other potential products if any are approved for marketing, competition from others developing products for similar uses, Inotek s ability to manage operating expenses,

Inotek s ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, Inotek s dependence on third parties for development, manufacture,

marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled Risk Factors in Inotek s most recent Quarterly

Report on Form 10-Q filed with the Securities and Exchange Commission as well as discussions of potential risks, uncertainties, and other important factors in Inotek s subsequent filings with the

Securities and Exchange Commission. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any

forward-looking statements, whether as a result of new information, future events or otherwise.

Claudine Prowse, PhD, 781-552-4305

Vice President, Corporate Development and IRO

Inotek Pharmaceuticals Corporation

(in thousands, except share and per share amounts)